The use of human albumin is common in hepatology since international scientific societies support its administration to treat or prevent severe complications of cirrhosis, such as the prevention of post-paracentesis circulatory dysfunction after large-volume paracentesis and renal failure induced by spontaneous bacterial peritonitis, and the treatment of hepatorenal syndrome in association with vasoconstrictors. However, these indications are often disregarded, mainly because the high cost of human albumin leads health authorities and hospital administrations to restrict its use. On the other hand, physicians often prescribe human albumin in patients with advanced cirrhosis for indications that are not supported by solid scientific evidence and/or are still under investigation in clinical trials. In order to implement appropriate prescription of human albumin and to avoid its futile use, the Italian Association for the Study of the Liver (AISF) and the Italian Society of Transfusion Medicine and Immunohaematology (SIMTI) nominated a panel of experts, who reviewed the available clinical literature and produced practical clinical recommendations for the use of human albumin in patients with cirrhosis.

AISF-SIMTI Position Paper: The appropriate use of albumin in patients with liver cirrhosis / Caraceni, Paolo; Angeli, Paolo; Prati, Daniele; Bernardi, Mauro; Liumbruno, Giancarlo Maria; Bennardello, Francesco; Piccoli, Pierluigi; Velati, Claudio; Alessandria, Carlo; Riggio, Oliviero; Salerno, Francesco; Berti, Pierluigi; Facco, Giuseppina; Fiorin, Francesco. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - 48:1(2016), pp. 4-15. [10.1016/j.dld.2015.11.008]

AISF-SIMTI Position Paper: The appropriate use of albumin in patients with liver cirrhosis

Riggio, Oliviero;
2016

Abstract

The use of human albumin is common in hepatology since international scientific societies support its administration to treat or prevent severe complications of cirrhosis, such as the prevention of post-paracentesis circulatory dysfunction after large-volume paracentesis and renal failure induced by spontaneous bacterial peritonitis, and the treatment of hepatorenal syndrome in association with vasoconstrictors. However, these indications are often disregarded, mainly because the high cost of human albumin leads health authorities and hospital administrations to restrict its use. On the other hand, physicians often prescribe human albumin in patients with advanced cirrhosis for indications that are not supported by solid scientific evidence and/or are still under investigation in clinical trials. In order to implement appropriate prescription of human albumin and to avoid its futile use, the Italian Association for the Study of the Liver (AISF) and the Italian Society of Transfusion Medicine and Immunohaematology (SIMTI) nominated a panel of experts, who reviewed the available clinical literature and produced practical clinical recommendations for the use of human albumin in patients with cirrhosis.
2016
Ascites; Hepatorenal syndrome; Post-paracentesis circulatory dysfunction; Spontaneous bacterial peritonitis; Acute Kidney Injury; Albumins; Ascites; Evidence-Based Medicine; Hepatic Encephalopathy; Hepatorenal Syndrome; Humans; Hyponatremia; Hypovolemia; Italy; Liver Cirrhosis; Paracentesis; Peritonitis; Shock; Hepatology; Gastroenterology
01 Pubblicazione su rivista::01a Articolo in rivista
AISF-SIMTI Position Paper: The appropriate use of albumin in patients with liver cirrhosis / Caraceni, Paolo; Angeli, Paolo; Prati, Daniele; Bernardi, Mauro; Liumbruno, Giancarlo Maria; Bennardello, Francesco; Piccoli, Pierluigi; Velati, Claudio; Alessandria, Carlo; Riggio, Oliviero; Salerno, Francesco; Berti, Pierluigi; Facco, Giuseppina; Fiorin, Francesco. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - 48:1(2016), pp. 4-15. [10.1016/j.dld.2015.11.008]
File allegati a questo prodotto
File Dimensione Formato  
Caraceni_AISF-SIMITI_2016.pdf

accesso aperto

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 808.02 kB
Formato Adobe PDF
808.02 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1066441
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 26
  • ???jsp.display-item.citation.isi??? 27
social impact